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Abstract
Background: Huntington's disease (HD) is an inherited neurodegenerative disorder triggered by
an expanded polyglutamine tract in huntingtin that is thought to confer a new conformational
property on this large protein. The propensity of small amino-terminal fragments with mutant, but
not wild-type, glutamine tracts to self-aggregate is consistent with an altered conformation but such
fragments occur relatively late in the disease process in human patients and mouse models
expressing full-length mutant protein. This suggests that the altered conformational property may
act within the full-length mutant huntingtin to initially trigger pathogenesis. Indeed, genotype-
phenotype studies in HD have defined genetic criteria for the disease initiating mechanism, and
these are all fulfilled by phenotypes associated with expression of full-length mutant huntingtin, but
not amino-terminal fragment, in mouse models. As the in vitro aggregation of amino-terminal
mutant huntingtin fragment offers a ready assay to identify small compounds that interfere with the
conformation of the polyglutamine tract, we have identified a number of aggregation inhibitors, and
tested whether these are also capable of reversing a phenotype caused by endogenous expression
of mutant huntingtin in a striatal cell line from the HdhQ111/Q111 knock-in mouse.
Results: We screened the NINDS Custom Collection of 1,040 FDA approved drugs and bioactive
compounds for their ability to prevent in vitro aggregation of Q58-htn 1–171 amino terminal
fragment. Ten compounds were identified that inhibited aggregation with IC50 < 15 µM, including
gossypol, gambogic acid, juglone, celastrol, sanguinarine and anthralin. Of these, both juglone and
celastrol were effective in reversing the abnormal cellular localization of full-length mutant
huntingtin observed in mutant HdhQ111/Q111 striatal cells.
Conclusions: At least some compounds identified as aggregation inhibitors also prevent a
neuronal cellular phenotype caused by full-length mutant huntingtin, suggesting that in vitro fragment
aggregation can act as a proxy for monitoring the disease-producing conformational property in
HD. Thus, identification and testing of compounds that alter in vitro aggregation is a viable approach
for defining potential therapeutic compounds that may act on the deleterious conformational
property of full-length mutant huntingtin.
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Huntington's disease (HD) is a severe, dominantly inher-
ited neurodegenerative disorder that typically has its onset
in mid-life, though it may occur in the juvenile years or in
the elderly, and that produces an inexorable decline to
death 10–20 years later [1]. Its cardinal clinical feature is
a characteristic motor disturbance involving progressive
choreoathetosis, but the disorder also involves psycholog-
ical changes and cognitive decline. The neuropathological
hallmark of HD is the loss of medium spiny striatal pro-
jection neurons in a dorso-ventral/medio-lateral gradient
that eventually decimates the caudate nucleus, but consid-
erable neuronal loss also occurs in other parts of the basal
ganglia and in the cortex [2]. The pathogenic process of
HD is initially triggered by an expanded polyglutamine
segment near the amino terminus of huntingtin, an ~350
kDa protein whose precise physiological function is
uncertain [3]. Huntingtin is required for normal embry-
onic development and neurogenesis, based on the lethal
consequences of mutational inactivation in the mouse [4-
6]. By contrast, the HD mutation itself does not impair
this developmental activity but rather produces a "gain-of-
function" that acts to cause the disorder [7]. Genotype-
phenotype studies of HD patients, in comparison with
other polyglutamine neurodegenerative disorders, have
delineated a number of genetic criteria for the mechanism
that triggers HD pathogenesis: 1) a threshold poly-
glutamine length (within a normal human lifespan); 2)
progressive severity with increasing polyglutamine length
above the threshold; 3) complete dominance over the
wild-type protein; 4) greater dependence on poly-
glutamine length than on huntingtin concentration
(within a physiological range) and 5) striatal selectivity,
due to the huntingtin protein context in which the poly-
glutamine tract is presented [8,9].
The "gain-of-function" due to the HD mutation is thought
to lie in a novel conformational property conferred on
mutant huntingtin by the expanded polyglutamine tract
[10]. This has been supported by in vitro studies of a small
amino-terminal huntingtin fragment, where an expanded
polyglutamine tract promotes self-aggregation in a man-
ner that conforms to the first four genetic criteria [10-12].
The in vitro aggregation involves a conformational change
of the polyglutamine segment from a random coil to an
amyloid structure and is paralleled in cell culture in some
ways by the formation of cytoplasmic and nuclear inclu-
sions that also incorporate other proteins [13]. Neuronal
inclusions containing amino-terminal fragment have also
been detected in HD brain, though their role in pathogen-
esis remains a matter of debate, as they may occur late in
the pathogenic process as a consequence of huntingtin
degradation [14].
Precise genetic modeling of HD in the mouse supports the
view that in vivo, the "gain-of-function" property con-
ferred by the expanded polyglutamine acts within full-
length huntingtin to cause abnormalities that do not ini-
tially involve formation of an insoluble aggregate [15,16].
Knock-in mice in which the HD mutation has been intro-
duced into Hdh, the mouse orthologue, display early bio-
chemical and histological phenotypes that are associated
with expression of full-length mutant huntingtin at nor-
mal physiological levels and in a normal developmental
pattern [7,15-20]. Indeed, the phenotypes associated with
expression of full-length mutant huntingtin in these mice,
and in neuronal progenitor cells derived from them, also
fulfill the genetic criteria for the mechanism triggering HD
pathogenesis [15,20-22] One of the earliest phenotypes is
the nuclear localization of full-length mutant huntingtin
in the nucleus of striatal neurons [16]. Together, the
knock-in mouse data suggest that the process of pathogen-
esis is triggered by the presence of expanded poly-
glutamine in full-length huntingtin and leads only after
many months to the formation of amino-terminal hunt-
ingtin fragment and inclusion formation [15].
We have postulated that the same conformational prop-
erty that promotes aggregation in the context of a small
fragment may also act with the context of full-length hunt-
ingtin to trigger pathogenesis, possibly by altering hunt-
ingtin's interaction with another cellular element.
Consequently, we have identified small molecules from
the NINDS Custom Collection of bioactive compounds
that inhibit in vitro aggregation of amino-terminal mutant
huntingtin [23]. These have been tested for their ability to
reverse the huntingtin localization phenotype associated
with full-length mutant huntingtin in cultured striatal
progenitor cells from Hdh knock-in mice. Our findings
indicate that some of these compounds reverse the effects
of the expanded polyglutamine in both assays and sup-
port the view that some inhibitors of polyglutamine
aggregation may lead to viable therapeutics targeted at
full-length mutant huntingtin, early in the disease
process.
Results
Screening for inhibitors of aggregation
We have previously demonstrated that, when released
from the protection of a GST fusion protein, the amino
terminal fragment 1–171 of mutant huntingtin, forms
aggregates in a manner consistent with the genetic criteria
for the mechanism of HD pathogenesis [10]. We used a
modified version of this assay, implemented using a 96-
well format ELIFA dot blot apparatus, to screen the
NINDS Custom Collection (NCC) which consists of 1040
small bioactive compounds, both FDA-approved drugs
and natural products (Figure 1A). The screening was car-
ried out in a blinded fashion as part of the NINDSPage 2 of 12
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Schematic diagram of the aggregation screening assay (A) and typical results (B) A: Scheme of an in vitro mutant 
huntingtin aggregation assay modified for drug screening. In the primary screening, the mixture of fusion protein, GST-Q58-
Htn (20 µg/ml) and Thrombin (0.5 unit/µg protein) was immediately distributed into the 96-well plates containing diluted com-
pounds at 40 µl/well. The final concentration of the small compounds is 100 µM. 10 µl of 10% SDS/50 mM 2-mercaptoethanol 
was added into each well to stop the reaction after 24 hours incubation at room temperature. The aggregates were separated 
by filtering through a cellulose acetate membrane (0.2 µm). Immunoblotting was done with a specific anti-huntingtin antibody, 
HP1, followed by incubation with peroxidase conjugated anti-rabbit antibody. The signals of the retained aggregates were 
scanned and quantified. In the secondary screening, compounds tested positive in were tested at 10 µM and a 45-minute incu-
bation at room temperature was followed after mixing the protein and enzyme. B: A typical immunoblot of the huntingtin 
aggregation inhibitor screening. The aggregates retained on the membrane were visualized by ECL. The intensity of dot reflects 
the amount of aggregates. The blot shows the positions of each drug in a 96-well plate. Congo Red: positive control (row E, col-
umn 12 and row F, column 12). DMSO: negative control (row G, column 12 and row H, column 12). Drugs in wells F2, E4, E9 and 
D3 are huntingtin aggregation inhibitors.
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identities of compounds in the NCC only being made
available after completion of the screens [23].
In our primary screen (Figure 1A), GST-Q58-Htn (20 µg/
ml) was mixed with thrombin (0.5 unit/µg GST-Q58-
Htn) and immediately dispensed into a 96-well PCR plate
containing compounds diluted to a final concentration of
100 µM. Incubation was continued for 24 hours at room
temperature to allow aggregate formation. The aggrega-
tion was stopped by 2% SDS/10 mM 2-mercaptoethanol
followed by boiling for 5 minutes. The mixture was fil-
tered through a cellulose acetate membrane by using a 96-
well ELIFA dot blot apparatus. The aggregates retained on
the membrane were detected and quantified by immuno-
blotting and subsequent image analysis. A typical immu-
noblot result is shown in Figure 1B. Congo Red, a known
huntingtin aggregation inhibitor, was used as the positive
control [24]. 10 µM Congo Red can completely inhibit the
Q58-Htn aggregation. DMSO, used for the negative con-
trol, had no impact on Q58-Htn aggregation.
Potential inhibitors were distributed evenly cross the
whole NCC library (Figure 2). Sixty compounds that
showed more than 50% inhibitory effect were selected to
be retested in a second screen at a lower concentration of
10 µM. The 8 compounds in column 5 of plate 9, were
missed in the primary screening at 100 µM, and were
therefore also tested in the second screening at 10 µM. In
the primary screening, a "hit" could have resulted either
from direct inhibition of polyglutamine-induced aggrega-
tion or indirectly, by inhibition of the thrombin and con-
sequent failure to cleave GST-Q58-Htn, which does not by
itself aggregate. Consequently, the second screening at 10
µM was carried out after thrombin digestion, to eliminate
thrombin inhibitors. Western blotting showed that more
than 95% of GST-Q58-Htn is cleaved by thrombin (at
ratio of 0.5 unit/1 µg protein) within 30 minutes (data
not shown). Consequently, the mixture of GST-Q58-Htn
and thrombin was preincubated for 45 minutes, followed
by centrifugation to remove any aggregates already
formed, before adding the test compounds. Nineteen of
the compounds tested at 10 µM, showed significant direct
inhibitory effects on aggregation. The 10 most potent
compounds, corresponding to a 'hit' rate of 1%, are
shown in Figure 3.
Characteristics of aggregation inhibitors
To determine the potency of each inhibitor, we performed
dose response assays at concentrations ranging from 0.01
µM to 500 µM. Representative curves for the 6 most
potent compounds are shown in Figure 4. Gambogic acid
and celastrol showed strong but incomplete inhibition
even at the maximum concentration, permitting approxi-
mately 20% residual aggregate to form. The average IC50
(half-maximal inhibition) values for the most potent 10
compounds, which range from 0.7 to 15 µM, were
obtained from at least two independent experiments each
(Figure 3). The most effective aggregation inhibitor was
gossypol-acetic acid complex, followed closely by gam-
bogic acid, and then juglone, celastrol, and sanguinarine
nitrate, which all had IC50 values less than 6 µM.
Effect on striatal cells expressing endogenous full-length 
mutant huntingtin
To test the hypothesis that compounds, which inhibit the
aggregation-promoting property of amino-terminal
mutant huntingtin will also rescue effects of full-length
mutant huntingtin, we tested the top six inhibitors in a
striatal cell-based assay. Mutant HdhQ111/Q111 and wild-
type HdhQ7/Q7 striatal cell lines, ST7/7 and ST111/111,
respectively, which have been prepared by transformation
with a tsSV40 vector, can be propagated in culture and
used for cytological and biochemical comparisons [25].
These cells express full-length mutant or wild-type hunt-
ingtin, respectively, with no evidence of truncated amino-
terminal fragments, no formation of polyglutamine aggre-
gates and no cell death-producing toxicity. However, like
the striatal neurons of HdhQ111/Q111 knock-in mice, the
ST111/111 cells show nuclear staining of huntingtin
when tested with an amino-terminal huntingtin antibody
that is sensitive to the conformation of the full-length pro-
tein (Figure 5A). By contrast, ST7/7 cells expressing wild
type huntingtin show both nuclear and cytoplasmic
immunostaining with the same huntingtin antibody (Fig-
ure 5A). This differential localization phenotype occurs
early in the cascade of events detected during the lifespan
of Hdh knock-in mice, months before the appearance of
huntingtin amino-terminal fragment, and fulfills the
genetic criteria from genotype-phenotype studies in HD
patients, including polyglutamine length progressiveness
and striatal specificity, suggesting that it follows from the
same property that triggers HD pathogenesis.
This huntingtin localization phenotype was used to mon-
itor the effect of inhibitors in the mutant cells (Figure 5B),
and the results are shown in Table 1. About 89% of ST7/7
striatal cells showed both nuclear and cytoplasmic immu-
nostaining signal, while ST111/111 striatal cells showed
only nuclear signal (99%). Of the six compounds tested,
celastrol and juglone both reversed the mutant phenotype
in a dose-dependent manner. Juglone showed no evident
cell toxicity up to 10 µM, where 68% of mutant cells had
reverted to wild-type phenotype. Celastrol reverted up to
81% of the cells but showed toxicity, killing ~4% of cells
at 10 µM. Gossypol acetic acid complex was less effective,
but showed no toxicity. At 50 µM, only 15% of the mutant
cells displayed the wild-type phenotype. Gambogic acid
showed a comparable small effect at 10 µM but was very
toxic at high concentration, as all cells were killed at 50Page 4 of 12
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effect on the huntingtin localization phenotype in this
assay.
Discussion
A dramatic marker of pathology in many neurodegenera-
tive disorders is the appearance of intracellular inclusions
in some surviving neurons [13]. In HD, these inclusions
stain positively for huntingtin, ubiquitin and a number of
other proteins, but are thought to be initiated by the
aggregation of an amino-terminal fragment of mutant
huntingtin, due to its expanded polyglutamine tract
[14,26-28]. A number of model systems have been devel-
oped to investigate the polyglutamine-driven aggregation
process and its consequences both in vitro and in vivo, but
it remains unclear in HD whether the formation of aggre-
gates plays an essential role in the pathway of pathogene-
sis or is a downstream by-product of neuronal
dysfunction induced by full-length mutant huntingtin
[29]. In either event, the search for drugs that alter in vitro
aggregation of amino-terminal huntingtin fragment is
attractive, since the aggregation-promoting physical prop-
erty exhibits characteristics comparable to the disease-pro-
ducing property of corresponding human alleles, as
defined from genotype-phenotype studies of HD patients.
For example, if accumulation of huntingtin inclusions is
the proximate cause of neuronal death, compounds that
inhibit aggregation would have therapeutic potential.
Conversely, if the inclusions are only a downstream
marker of the pathogenic process, the same drugs may still
have therapeutic potential if they act on the property of
full-length mutant huntingtin that triggers pathogenesis.
It was with a view to testing whether the in vitro aggrega-
tion assay could act as a proxy for monitoring the disease-
producing property of mutant huntingtin that we under-
took this study.
Distribution of potential huntingtin aggregation inhibitors in the NCC libraryFigure 2
Distribution of potential huntingtin aggregation inhibitors in the NCC library. Most compounds show no or little 
inhibitory effect on huntingtin aggregation. The potential inhibitors are evenly distributed across the whole chemical library. 
Due to very high background on particular regions of some dot blotting membranes, some compounds (compounds around 
200) show a high apparent promotional effect that is artefactual (as shown in ~-70% inhibition). The 8 compounds located in 
column 5 of plate 9 were missed and were tested in the second screening at 10 µM.
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BMC Neuroscience 2005, 6:1 http://www.biomedcentral.com/1471-2202/6/1A comparable screening assay to the one used here has
been employed to screen a large chemical library and has
demonstrated the feasibility of identifying small molecule
inhibitors of polyglutamine aggregation, including a fam-
ily of benzothiazole-related compounds [30]. However,
the long, arduous and expensive process of developing
compounds for use as drugs in humans prompted us to
screen a smaller chemical library biased toward drugs
already approved by the U.S. Food and Drug Administra-
tion. The aggregation-inhibiting compounds that we
identified came from a collection of mostly FDA-
approved compounds and bioactive natural products that
were specifically assembled for a neurodegenerative
disease drug screening consortium supported by the
National Institute for Neurological Disorders and Stroke
and several disease foundations, including the Hunting-
ton's Disease Society of America [23]. The drugs were dis-
tributed to 27 different labs for blinded testing in assays
of potential relevance to neurodegenerative disease.
Unfortunately, despite the preponderance of FDA
approved drugs in the collection, none of our top hits
(IC50 < 10 µM) is a compound approved for internal use
in humans. The most effective inhibitor of aggregation
was gossypol-acetic acid complex. Gossypol, a polyphe-
nol found in cottonseed, has been studied extensively as a
male contraceptive in China but the World Health Organ-
ization has argued against its use because of induced
hypokalemia, high toxicity and the risk of permanent ste-
rility [31]. Almost as potent, gambogic acid is a complex
ring-structured natural product that is the main active
ingredient of gamboge resin from the Garcinia hanburyi
Ten most potent aggregation inhibitors from the NCC libraryFigure 3
Ten most potent aggregation inhibitors from the NCC library
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BMC Neuroscience 2005, 6:1 http://www.biomedcentral.com/1471-2202/6/1tree. It has long been used as a pigment for painting and
in traditional medicine as a potent purgative. Recently, it
was identified in a high-throughput screen as an apoptosis
inducer with potential for development as an anti-cancer
agent [32]. Juglone is a napthoquinone found in the bark
of the black walnut (Juglans nigra), which has been used as
an herbal medicine for its antihaemorrhagic and antifun-
gal properties [33]. Celastrol is a triterpenoid from the
vine Tripterygium wilfordii used as an alternative medicine
for rheumatoid arthritis that has anti-oxidant, anti-
inflammatory activity, immunosuppressive and anti-ang-
iogenic activities. It has been proposed as worthy of explo-
ration as a therapeutic in Alzheimer disease [34].
Sanguinarine, a benzophenanthridine alkaloid from
Dose-response curve of mutant huntingtin aggregation inhibitorsFigure 4
Dose-response curve of mutant huntingtin aggregation inhibitors. Compounds were added in 1 µl DMSO to 40 µl 20 
µg/ml (0.25 µM) GST-Q58-Htn pre-incubated with thrombin. The reaction was carried out at room temperature for 24 hours. 
The intensity of each dot of the dot blot was normalized to the DMSO control. Assays were performed twice, in triplicate at 
each concentration each time (n = 6).
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BMC Neuroscience 2005, 6:1 http://www.biomedcentral.com/1471-2202/6/1Localization of huntingtin in wild type and mutant striatal cell from knock-in miceFigure 5
Localization of huntingtin in wild type and mutant striatal cell from knock-in mice. Cells were cultured for 48 
hours and immunostaining was done with a specific antibody against huntingtin, AP229, followed by Cy3 labeled secondary anti-
body. The signal was visualized by confocal microscopy (magnification: ×20). A. The localization of full-length huntingtin of stri-
atal cell lines: ST7/7 and ST111/111 with 2.5% DMSO. B. The localization of huntingtin of mutant striatal cell, ST111/111, after 
treated with drugs at 10 µM.Page 8 of 12
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BMC Neuroscience 2005, 6:1 http://www.biomedcentral.com/1471-2202/6/1bloodroot (Sanguinaria canadensis) has broad antimicro-
bial and anti-inflammatory, as well as potential anti-ang-
iogenic activity [35]. It has been used as an oral rinse and
as a potential antigingivitis/antiplaque agent in tooth-
paste [36]. Anthralin is a synthetic derivative of chrysar-
obin, a traditional remedy for various skin ailments from
Andira araroba, that has been widely used as topical treat-
ment for psoriasis and alopecia areata [37,38].
Although none of these bioactive compounds is a candi-
date for immediate human trials, they provided a means
to test whether compounds that inhibit polyglutamine
aggregation might also block the neuronal phenotype
caused by an elongated polyglutamine tract in full-length
huntingtin. While we do not have a direct physical meas-
ure of huntingtin conformation and it remains possible
that compounds could reverse the cellular phenotype by
different pathways, our finding that juglone and celastrol,
two drugs of different structure selected as hits in our pri-
mary aggregation assay, are both effective at restoring
cytoplasmic huntingtin staining in the striatal cell assay
suggests that they both act via a conformational property
of mutant huntingtin. That gossypol, gambogic acid,
sanguinarine and anthralin were not effective could be
due to any of a number of reasons, including cellular
uptake, toxicity, interaction with other cellular compo-
nents, etc. However, it may also indicate that these com-
pounds do not directly modify the conformational
property of mutant huntingtin, but instead block a differ-
ent step in the in vitro aggregation process or that they do
so by a different physical effect than juglone and celastrol.
A detailed analysis of structure-activity relationships using
structurally-related compounds and testing in vivo in
knock-in mice for their ability to reverse the cascade of
mutant huntingtin-associated phenotypes will be needed
to adequately assess the potential of any of these different
types of compounds for testing in HD clinical trials.
The remaining compounds identified as weaker aggrega-
tion blockers in our primary screen include selamectin, a
veterinary anti-parasitic [39], pararosaniline pamoate, a
treatment for schistosomiasis [40], tyrothricin, a cyclic
peptide antibiotic, and meclocycline, a tetracycline-
related antibiotic. The latter is of particular interest since
it was the most potent of several tetracycline-related anti-
biotics present among the NCC compounds, including
tetracycline, chlortetracycline, demeclocycline, doxycy-
cline, methacycline, oxytetracycline and notably,
minocycline, which has been proposed as a therapeutic in
HD and other neurodegenerative disorders. Minocycline
is an FDA approved antibiotic used for a variety of infec-
tions that has variably been reported to improve symp-
toms in the R6/2 exon 1 overexpression HD model [41-
44]. It has anti-inflammatory and anti-apoptotic activity
that has been proposed to involve several potential mech-
anisms of action. In our hands, minocycline is a weak
inhibitor of polyglutamine aggregation with an IC50 of 43µM (unpublished data). This is consistent with the inhib-
itory effect on huntingtin exon 1 aggregation reported pre-
viously at 30 µM in long-term hippocampal slice cultures
from the R6/2 mouse [44]. Two safety and tolerability
studies of minocycline in human HD are completed
[45,46] and can be expected to lead to efficacy trials earlier
than any trials for strong aggregation inhibitors. However,
it is conceivable that long-term, low level inhibition of
mutant huntingtin's aggregation-promoting conforma-
tional property, independent of minocycline's anti-apop-
totic activity, may be sufficient to alter detectably the
timing of disease onset or early progression. If the hoped
for positive results are obtained in minocycline HD trials,
Table 1: Percentage of ST111/111 cells showing cytoplasmic/nuclear huntingtin localization comparable to wild-type ST7/7 cells in 
response to chemical treatment*
Compounds Concentration (µM)
0.5 5 10 50
Gossypol-acetic acid 0 4.5 ± 4.3% 3.5 ± 3.5% 15.9 ± 11.1%
Gambogic acid 1 ± 2.6% 0 2.1 ± 4.6% Toxic (100%)
Juglone 10.4 ± 12.4% 37.9 ± 19.9% 68.8 ± 18.4% N.A.
Celastrol 8.7 ± 8.7% 69.2 ± 3.8% (1%) 78.1 ± 3.5% (4%) N.A.
Sanguinarine 0 (4.3%) 3.7 ± 5.2% (5.5%) 0 (22.5%) N.A.
Anthralin 4.6 ± 7.6% 6.6 ± 9.7% 9.6 ± 12.1% 11.8 ± 14.4%
ST111/111 cells with both nuclear and cytoplasmic staining were counted, as well as total cells and dead cells. The effectiveness of the drugs was 
measured by percentage of cells with nuclear and cytoplasmic staining versus total cells. In untreated cultures, 89% of ST7/7 striatal cells show both 
nuclear and cytoplasmic immunostaining, while only 1% of ST111/111 striatal cells show this pattern. Entries in the table represent the average 
values from 5–10 different microcope fields ± standard deviation. Numbers in brackets indicate percentage of dead cells in cases where toxicity was 
observed.Page 9 of 12
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BMC Neuroscience 2005, 6:1 http://www.biomedcentral.com/1471-2202/6/1this alternative mechanism should be considered since it
would have implications for testing of meclocycline and
for assessing the potential trade-off between potency and
toxicity in choosing other aggregation inhibitors as poten-
tial long-term therapeutics.
Interestingly, the same set of 1040 NCC compounds were
screened for their ability to block toxicity in a PC12 cellu-
lar assay where induced expression of huntingtin exon 1
encoding 103 glutamines leads to the accumulation of
aggregates and rapid cell death [47]. Although eighteen
compounds were found to be completely protective, none
was among our hits, suggesting that the mechanism of
polyglutamine toxicity in the PC12 cells is fundamentally
different than the mechanism(s) involved in the in vitro
aggregation assay. Among a secondary class of partially
protective compounds in the PC12 assay, only celastrol
overlapped with our hits. The NCC compounds were also
screened in a cellular assay in HEK 293T cells expressing
androgen receptor with 112 glutamines [48]. In this
model for spinal bulbar and muscular atrophy, accumula-
tion of intracellular inclusions, accompanied by caspase 3
activation, is followed by cell death within 72 hours.
Twenty compounds that blocked caspase 3 activation
included celastrol, gambogic acid, sanguinarine and
tyrothricin, though all but sanguinarine showed toxicity.
The major finding from this assay was that several cardiac
glycosides were protective, presumably by a different
mechanism than our hits. Indeed, although most of the
assays in the NINDS consortium involved disorders asso-
ciated with protein aggregation, including various
polyglutamine disorders, amyotrophic lateral sclerosis
and Parkinson disease, there was a remarkable lack of
overlap in hits suggesting that the individual assays tar-
geted fundamentally different mechanisms. A possible
exception was celastrol, which was found as a hit in our
aggregation assay, the two assays noted above, and other
assays which will be discussed in a summary article
describing the consortium.
Conclusions
The identification and further characterization of chemi-
cal inhibitors of in vitro aggregation of an amino-terminal
fragment of mutant huntingtin offer promise for the
development of potentially therapeutic compounds that
also target the deleterious conformational property of
full-length mutant huntingtin.
Methods
Chemical library, enzymes and antibodies
A library containing 1040 small chemical compounds
consisting of FDA-approved drugs and bioactive natural
products, the National Institute of Neurodegenerative
Diseases and Stroke Custom Collection (NCC), was pro-
vided in thirteen 96-well plates by MicroSource Discovery
Systems, Inc (Gaylordsville CT). The complete list of NCC
compounds is available [49]. All compounds were dis-
solved in 100% DMSO at a concentration of 10 mM.
Thrombin was purchased from Amersham Pharmacia
Biotech (Piscataway NJ). Anti-huntingtin antibody HP1,
used in the screening assay was described by Persichetti et
al. [50]. AP229 used in the cell-based assay was previously
described and was a gift of Dr. A.H. Sharp [25].
GST-huntingtin construct and expression
A recombinant pGEX-2TK expression vector with cDNA
fragment encoding amino terminal 171 amino acids of
human huntingtin with a polyglutamine tract of 58 was
used to prepare the GST-Q58-htn fusion protein. The
GST-Q58-htn was overexpressed in BL21 cells and puri-
fied by affinity chromatography over glutathione-sepha-
rose 4B beads (Amersham Pharmacia Biotech). The
purified proteins were stored at concentration of 2.0 mg/
ml at -80°C.
Aggregation assay
For primary screening of the chemical library, 1 µl of 4.0
mM small compound stock, diluted from the original
plates, was placed in wells of 96-well plates. The fusion
protein, GST-Q58-Htn was mixed with thrombin (0.5
unit/1 µg protein) at a concentration of 20 µg/ml in a
buffer of 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2.5 mM
CaCl2, 1.0 mM EDTA. The mixture was immediately dis-
tributed into the 96-well plates containing diluted com-
pounds at 40 µl/well and mixed well. The final
concentration of the small compounds was 100 µM. After
24 hours incubation at room temperature, the reaction
was stopped by adding 10 µl of 10% SDS/50 mM 2-mer-
captoethanol to each well followed by boiling in a PCR
machine for 5 minutes. The mixture from each well was
filtered through a cellulose acetate membrane ((0.2 µm,
GE Osmonics labstore, Minnetonka MN) by using a 96-
well ELIFA (Pierce Biotech). The aggregates retained on
the membrane were detected by a specific anti-huntingtin
antibody, HP1 (diluted 1:1000), followed by incubation
with peroxidase conjugated anti-rabbit antibody (diluted
1:10,000, Sigma). Signals from SDS insoluble aggregates
were scanned and quantified by using ImageMaster Tota-
lab image analysis software (Amersham Pharmacia Bio-
tech). In the secondary screening, all steps were the same
except the final concentration of compound in each well
was reduced to 10 µM and the GST-Q58-Htn/thrombin
mixture was preincubated for 45-minutes at room tem-
perature and clarified by centrifugation at 28,000 × g for
30 minutes before being added to the test wells. For IC50
determinations, the in vitro aggregation assay and signal
quantification were performed as in the second screening
but varying the final concentration of input drug. The data
for each inhibitor were obtained from at least two inde-
pendent experiments in which every sample was analyzedPage 10 of 12
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Inc., San Diego, CA).
Striatal cell line assay
Conditionally immortalized wild-type HdhQ7/Q7 striatal
neuronal progenitor cells (ST7/7) expressing endogenous
normal huntingtin, and homozygous HdhQ111/Q111 striatal
neuronal progenitor cells (ST111/111), expressing endog-
enous mutant huntingtin with 111-glutamines, have been
described previously [25]. The striatal cell lines were
grown at 33°C in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10 % fetal bovine serum
(FBS), 1% nonessential aminoacids, 2 mM L-glutamine
and 400 µg/ml G418 (Geneticin (GIBCO-BRL, Life Tech-
nologies, Gaithersburg, MD).
In the immunofluorescence and confocal analysis experi-
ment, wild-type ST7/7 and homozygous mutant ST111/
111 cells, grown to confluence on glass coverslips, were
treated with 6 different drugs at four different concentra-
tions (0.5, 5, 10 or 50 µM) for 30 min at 33°C. After the
treatment the drugs were removed and the cells washed
twice in PBS. The cells were then fixed by incubation in
4% formaldehyde for 15 min, permeabilized by 0.1%
Triton X-100 for 5 min and incubated for 30 min with
blocking solution (1% bovine albumin in PBS). Cover-
slips were then incubated in primary antibody (AP229
1:500 dilution) for 2 h at room temperature and washed
three times in PBS before a further 1 h in blocking solu-
tion containing the secondary antibody (goat anti-rabbit
Cy3, Jackson ImmunoResearch, West Grove, PA. USA).
After three washes in PBS coverslips were mounted onto
glass slides with Vectashield (Burlingame, CA. USA) and
the images were analyzed with a laser confocal micro-
scope (Bio-Rad, Hercules, CA. USA) using 20 × objective.
Cell death was quantified by scoring the percentage of
cells with apoptotic nuclear morphology, i.e. condensed
or fragmented nuclei, under the confocal microscope. In
each case five to ten randomly selected fields were
counted, comprising at least 200 cells, and each experi-
ment was repeated 3 times.
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